New attack on EU plans for patient drug information
The European Commission has been told that the “only rationale” for its current plans to ease certain controls on the provision of prescription drug information to the public “seems to be to benefit the commercial interests of pharmaceutical companies by expanding their markets and helping them to build brand loyalty.”
Read article at pharmatimes.com (UK)
var sc_project=1725605;
var sc_invisible=0;
var sc_partition=16;
var sc_security="acf71b9a";